Leviticus Partners Amends HBIOS Stake on Jan 16 Event
Ticker: HBIO · Form: SC 13G/A · Filed: Jan 22, 2024 · CIK: 1123494
| Field | Detail |
|---|---|
| Company | Harvard Bioscience Inc (HBIO) |
| Form Type | SC 13G/A |
| Filed Date | Jan 22, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, passive-investment
TL;DR
**Leviticus Partners LP just updated their HBIOS holdings, watch for potential shifts.**
AI Summary
Leviticus Partners LP, a New York-based investment firm, filed an amended Schedule 13G/A on January 22, 2024, indicating a change in their beneficial ownership of Harvard Bioscience Inc. (HBIOS) common stock. This amendment, filed due to an event on January 16, 2024, updates their previous filing and is important for investors as it signals a potential shift in a significant holder's position, which could influence market perception or future stock performance.
Why It Matters
This filing shows an institutional investor, Leviticus Partners LP, has updated their stake in Harvard Bioscience Inc., which can signal their evolving confidence in the company's future.
Risk Assessment
Risk Level: low — An amended 13G filing typically indicates a passive investment change and does not inherently pose a high risk to the company or its shareholders.
Analyst Insight
Investors should monitor subsequent filings from Leviticus Partners LP for any further changes in their ownership percentage, as a significant increase or decrease could signal a shift in their investment strategy for Harvard Bioscience Inc.
Key Numbers
- 416906105 — CUSIP Number (identifies Harvard Bioscience Inc.'s common stock)
- 0001019432-24-000002 — Accession Number (unique identifier for this specific SEC filing)
Key Players & Entities
- Leviticus Partners LP (company) — the investment firm filing the SC 13G/A amendment
- Harvard Bioscience Inc. (company) — the subject company whose common stock is being reported
- AMH Equity LLC (company) — a former group member listed in the filing
- January 16, 2024 (date) — the date of the event requiring the filing
- January 22, 2024 (date) — the filing date of the SC 13G/A
Forward-Looking Statements
- Leviticus Partners LP will maintain a significant, passive stake in Harvard Bioscience Inc. for the foreseeable future. (Leviticus Partners LP) — medium confidence, target: 2025-01-22
FAQ
What type of filing is this and who filed it?
This is an SC 13G/A (Amendment No. 1) filing, which is an amendment to a Schedule 13G. It was filed by Leviticus Partners LP, a New York-based investment firm.
Which company's stock is the subject of this filing?
The subject company is Harvard Bioscience Inc., identified by the CUSIP Number 416906105 and the Central Index Key (CIK) 0001123494.
What was the date of the event that triggered this filing?
The date of the event which required the filing of this statement was January 16, 2024.
When was this amended filing submitted to the SEC?
This amended filing was submitted to the SEC on January 22, 2024, as indicated by the 'FILED AS OF DATE' and 'DATE AS OF CHANGE'.
Under which rule was this Schedule 13G/A filed?
This Schedule 13G/A was filed under Rule 13d-i(b) of the Securities Exchange Act of 1934, as indicated by the '/X/ Rule 13d-i(b)' checkbox.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 22, 2024 regarding HARVARD BIOSCIENCE INC (HBIO).